SI1934236T1 - Heterobifunkcionalni inhibitorji pan-selektina - Google Patents

Heterobifunkcionalni inhibitorji pan-selektina

Info

Publication number
SI1934236T1
SI1934236T1 SI200631510T SI200631510T SI1934236T1 SI 1934236 T1 SI1934236 T1 SI 1934236T1 SI 200631510 T SI200631510 T SI 200631510T SI 200631510 T SI200631510 T SI 200631510T SI 1934236 T1 SI1934236 T1 SI 1934236T1
Authority
SI
Slovenia
Prior art keywords
selectin inhibitors
heterobifunctional
pan
heterobifunctional pan
selectin
Prior art date
Application number
SI200631510T
Other languages
English (en)
Inventor
John L. Magnani
John T. Patton Jr.
Arun K. Sarkar
Sergei A. Svarovsky
Beat Ernst
Original Assignee
Glycomimetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics, Inc. filed Critical Glycomimetics, Inc.
Publication of SI1934236T1 publication Critical patent/SI1934236T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
SI200631510T 2005-09-02 2006-09-01 Heterobifunkcionalni inhibitorji pan-selektina SI1934236T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71399405P 2005-09-02 2005-09-02
EP06814078A EP1934236B1 (en) 2005-09-02 2006-09-01 Heterobifunctional pan-selectin inhibitors
PCT/US2006/034274 WO2007028050A1 (en) 2005-09-02 2006-09-01 Heterobifunctional pan-selectin inhibitors

Publications (1)

Publication Number Publication Date
SI1934236T1 true SI1934236T1 (sl) 2013-02-28

Family

ID=37603124

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631510T SI1934236T1 (sl) 2005-09-02 2006-09-01 Heterobifunkcionalni inhibitorji pan-selektina
SI200632228T SI2264043T1 (sl) 2005-09-02 2006-09-01 Heterobifunkcionalni inhibitorji pan-selektina

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200632228T SI2264043T1 (sl) 2005-09-02 2006-09-01 Heterobifunkcionalni inhibitorji pan-selektina

Country Status (16)

Country Link
US (6) US7728117B2 (sl)
EP (2) EP2264043B1 (sl)
JP (2) JP5209476B2 (sl)
CN (2) CN101287741B (sl)
AU (1) AU2006284578B2 (sl)
CA (1) CA2670130A1 (sl)
CY (1) CY1119721T1 (sl)
DK (2) DK2264043T3 (sl)
ES (2) ES2397850T3 (sl)
HK (1) HK1122041A1 (sl)
HU (1) HUE038246T2 (sl)
LT (1) LT2264043T (sl)
PL (2) PL1934236T3 (sl)
PT (2) PT1934236E (sl)
SI (2) SI1934236T1 (sl)
WO (1) WO2007028050A1 (sl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2397850T3 (es) 2005-09-02 2013-03-11 Glycomimetics, Inc. Inhibidores de pan-selectina heterobifuncionales
JP5298020B2 (ja) * 2006-10-12 2013-09-25 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの糖模倣体置換
EP2117561A1 (en) * 2007-02-09 2009-11-18 GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2009073911A1 (en) 2007-12-10 2009-06-18 Mater Medical Research Institute Treatment and prophylaxis
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8518896B2 (en) * 2008-06-13 2013-08-27 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
JP5726171B2 (ja) * 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2012061662A1 (en) 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
KR102055958B1 (ko) * 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
US20140059130A1 (en) * 2012-08-22 2014-02-27 Mainsoft R&D Ltd. System and method for updating connections in social networks
AU2013355238B2 (en) 2012-12-07 2017-12-14 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
US20170296566A9 (en) * 2013-09-30 2017-10-19 Glycomimetics, Inc. Methods and compositions for treating and/or preventing mucositis
EP3569609A1 (en) 2014-12-03 2019-11-20 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2016164394A1 (en) 2015-04-08 2016-10-13 Glycomimetics, Inc. 2-halo-galactose-containing selectin antagonists
US20160331775A1 (en) * 2015-05-14 2016-11-17 The Regents Of The University Of Michigan E-selectin inhibition works in combination with low-molecular weight heparin to decrease venous thrombosis and bleeding risk
WO2016196221A1 (en) 2015-05-29 2016-12-08 Nike Innovate C.V. System for operating multiple transceiver modules concurrently
JP2019501130A (ja) * 2015-12-02 2019-01-17 グリコミメティクス， インコーポレイテッド トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤
HUE050811T2 (hu) 2015-12-07 2021-01-28 Merck Patent Gmbh Avelumab anti-PD-1 ellenanyagot tartalmazó vizes gyógyászati kiszerelés
JP2019502727A (ja) 2016-01-22 2019-01-31 グリコミメティクス， インコーポレイテッド Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
WO2017205269A1 (en) 2016-05-24 2017-11-30 Glycomimetics, Inc. Haloalkyl fucose-containing selectin antagonists
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
KR102653723B1 (ko) 2016-10-07 2024-04-01 글리코미메틱스, 인크. 매우 강력한 다량체성 e-셀렉틴 길항물질
CA3054605A1 (en) * 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) * 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
WO2020123435A2 (en) 2018-12-10 2020-06-18 Glycomimetics, Inc. Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2020150263A1 (en) 2019-01-14 2020-07-23 Magnani John L Selectin or galectin antagonists for treating cytokine release syndrome and crs-induced neurotoxicity
WO2020219419A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Multimeric pan–selectin antagonists
EP3958978A1 (en) 2019-04-24 2022-03-02 GlycoMimetics, Inc. Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
US20220265691A1 (en) 2019-07-12 2022-08-25 Glycomimetics, Inc. Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
CA3146048A1 (en) 2019-07-31 2021-02-04 Glycomimetics, Inc. Use of e-selectin antagonists to enhance the survival of reconstituted, bone marrow-depleted hosts
WO2021195465A1 (en) * 2020-03-27 2021-09-30 Magnani John L Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
CN115666584A (zh) 2020-05-31 2023-01-31 糖模拟物有限公司 用于减少癌细胞负荷和保护正常血细胞生成的化合物和方法
AU2021292458A1 (en) 2020-06-14 2023-01-19 GlycoMimetics Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
CN116113637A (zh) * 2020-09-17 2023-05-12 糖模拟物有限公司 E-选择素靶向剂
WO2023014690A1 (en) 2021-08-03 2023-02-09 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2510745A (en) * 1945-11-15 1950-06-06 Charles R Kilgore Cover for electric service outlets
US2514745A (en) * 1946-12-19 1950-07-11 Heyer Ind Inc Changeable scale electrical testing instrument
US2757817A (en) * 1954-04-29 1956-08-07 Warren R Egan Electrical outlet box
US2983399A (en) * 1959-04-20 1961-05-09 Frank E Slater Seal for electric outlet box
US4109095A (en) * 1976-10-28 1978-08-22 Mulberry Metal Products, Inc. Weatherproof electrical outlet box cover
US4098423A (en) * 1977-03-10 1978-07-04 Louis Marrero Self-aligning outlet box assembly
US4145857A (en) * 1977-10-28 1979-03-27 Concast, Inc. Base for mounting electrical equipment
US4276730A (en) * 1979-07-02 1981-07-07 Lewis David M Building wall construction
US4320606A (en) * 1979-12-06 1982-03-23 Home Crafts Corporation Reinforced concrete panels and building constructed therewith
US4331832A (en) * 1980-01-10 1982-05-25 Sedco Pipe Products, Inc. Electrical outlet box
DE3020441A1 (de) 1980-05-29 1981-12-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von nitronaphthalin-sulfonsaeuren
US4458460A (en) * 1981-05-26 1984-07-10 Raceway Components, Inc. Cable module device
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4443654A (en) * 1981-10-19 1984-04-17 Butler Manufacturing Company Flush floor fitting
US4424407A (en) * 1981-11-30 1984-01-03 Barbic Mark J Electrical outlet safety cover
US4505403A (en) * 1984-05-29 1985-03-19 Slater Electric, Inc. Weatherproof electrical receptacle cover
US4603789A (en) * 1985-01-09 1986-08-05 Medlin Sr Lewis B Extension bracket for mounting electrical outlet box
DK17885D0 (da) 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US4876199A (en) 1985-04-04 1989-10-24 Fred Hutchinson Cancer Research Center Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain
CA1260596A (en) * 1985-06-20 1989-09-26 Christopher Teron Electrical box
US4634015A (en) * 1985-07-15 1987-01-06 Taylor Jerald M Adjustable electric outlet box
US4851511A (en) * 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
EP0249008B1 (de) 1986-05-09 1993-09-15 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore
US4803307A (en) * 1987-06-29 1989-02-07 Shotey Michael J Weatherproof outlet cover
US4988832A (en) * 1987-06-29 1991-01-29 Shotey Michael J Recessed electrical outlet with cover
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US4918259A (en) * 1988-08-19 1990-04-17 Hanson William L Electrical outlet box extension cover
US4931597A (en) * 1988-12-12 1990-06-05 Square D Company Junction boxes
EP0381310A1 (en) 1989-01-30 1990-08-08 The Biomembrane Institute Monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides and method for production thereof
US5012043A (en) * 1989-02-21 1991-04-30 Seymour Michael R Adjustable outlet box assembly and method of application
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP0408859B1 (en) 1989-05-23 1995-08-09 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies to activated endothelial cells
US5119606A (en) * 1989-06-22 1992-06-09 Graham Tom S Insulated concrete wall panel
US5117996A (en) * 1989-06-22 1992-06-02 Mcshane William J Electrical box extension
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5088246A (en) * 1990-04-10 1992-02-18 Brown Noel S Access box for conduits
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
WO1991019501A1 (en) 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US6391857B1 (en) * 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) * 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
ATE224911T1 (de) 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5648344A (en) * 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5143712A (en) 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
NZ240316A (en) 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
BR9106995A (pt) * 1990-11-23 1993-08-24 Gen Hospital Corp Inibicao de interacoes proteina-carboidrato com adesao celular
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5222338A (en) * 1991-03-12 1993-06-29 Hull Harold L Prefabricated concrete wall
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5318890A (en) * 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
AU660995B2 (en) * 1991-05-06 1995-07-13 Genentech Inc. Glycam-1 (Sgp 50), a selectin ligand
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
US5580858A (en) 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
CA2118695A1 (en) * 1991-09-10 1993-03-18 George A. Heavner Peptide inhibitors of inflammation mediated by selectins
US5268364A (en) 1991-12-12 1993-12-07 The Biomembrane Institute Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification
EP0602194A1 (en) 1991-12-18 1994-06-22 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
CA2100412A1 (en) 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
CA2144180A1 (en) * 1992-09-08 1994-03-17 George A. Heavner Peptide inhibitors of cellular adhesion
US5519008A (en) * 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
AU4859793A (en) 1992-09-11 1994-04-12 Regents Of The University Of California, The Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5293003A (en) * 1992-10-08 1994-03-08 Prairie Jr Marshall J Electrical box extender
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
ATE173630T1 (de) * 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US5412123A (en) * 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
US5763413A (en) * 1993-03-04 1998-06-09 Mect Corporation Lewis-associated compound, process for producing the same, and anti-inflammatory
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5854218A (en) 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9301677L (sv) 1993-05-14 1994-11-18 Kurt G I Nilsson Syntesmetod
EP0698031A4 (en) 1993-05-14 1997-07-09 Cytel Corp SIALYL LEx ANALOGS AS INHIBITORS OF CELLULAR ADHESION
CA2162600C (en) * 1993-05-17 2000-07-11 Chrales W. Rittershaus Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5646248A (en) * 1993-06-08 1997-07-08 La Jolla Cancer Research Foundation E-selection binding soluble lamp-1 polypeptide
US5658880A (en) 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5789385A (en) 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5679321A (en) 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5508387A (en) 1993-08-04 1996-04-16 Glycomed Incorporated Selectin binding glycopeptides
US5420376A (en) * 1993-08-06 1995-05-30 The Lamson & Sessions Co. Plastic electrical box for installation in poured concrete
US5827837A (en) 1993-08-20 1998-10-27 The Regents Of The University Of California Polyanion anti-inflammatory agents
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5434359A (en) * 1993-09-20 1995-07-18 Hubbell Incorporated Electrical box
CA2173990A1 (en) 1993-10-12 1995-04-20 Narasinga Rao A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5663151A (en) 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
DE4408248A1 (de) 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
EP0671409A3 (de) 1994-03-11 1996-06-12 Hoechst Ag Malonsäurederivate mit antiadhäsiven Eigenschaften.
HUT77345A (hu) 1994-04-29 1998-03-30 Texas Biotechnology Corporation E-szelektin, P-szelektin vagy L-szelektin szialil-Lewis x-hez vagy szialil-Lewis a-hoz kapcsolódását gátló mannopiranoziloxi-bifenil származékok és ezeket tartalmazó gyógyszerkészítmények
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
JPH0899989A (ja) 1994-09-30 1996-04-16 Akira Hasegawa 新規糖脂質誘導体およびその製造用中間体
US5906287A (en) * 1994-10-03 1999-05-25 Kohnen; Stephen J. Junction box construction for use in curved structures
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5639734A (en) * 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
MX9704893A (es) 1994-12-28 1997-10-31 Sumitomo Pharma Derivados de lewis x y procesos para producir los mismos.
US5648248A (en) * 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US5883331A (en) * 1995-01-12 1999-03-16 Reiker; Kenneth H. Electrical box with fixture support having an extension thereon
US20020040008A1 (en) * 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US6207894B1 (en) * 1995-01-31 2001-03-27 Reiker Enterprises Of Northwest Florida Inc. Load supporting electrical box system suited for installation in concrete and having enlarged cavity therein
US5527936A (en) 1995-02-17 1996-06-18 E. I. Du Pont De Nemours And Company Hydrosilylation of unsaturated compounds
GB9504065D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
US5509560A (en) * 1995-06-01 1996-04-23 Nash; William L. Gangable plastic box for electrical outlets
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
AU707474B2 (en) * 1995-06-29 1999-07-08 Novartis Ag Diglycosylated 1,2-diols as mimetics of sialyl-lewis X and sialyl-lewis A
EP0840606B1 (en) 1995-06-29 2000-06-07 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
US5876715A (en) 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
DE19532902A1 (de) * 1995-09-06 1997-03-13 Hoechst Ag Neuartige Glycomimetika als Selektin-Antagonisten und daraus hergestellte entzündungshemmend wirkende Arzneimittel
DE19537334A1 (de) * 1995-10-09 1997-04-10 Hoechst Ag Antiadhäsive Piperidin- und Pyrrolidin-Carbonsäuren
US5778625A (en) * 1995-10-13 1998-07-14 Bega/Us, Inc. Recessed lighting fixture and method of installing
AU7445796A (en) 1995-10-18 1997-05-07 Cytel Corporation Sialyl lex analogues as inhibitors of cellular adhesion
US5919769A (en) * 1995-10-26 1999-07-06 Kanebo, Ltd Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
US5747463A (en) * 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
DE19602355A1 (de) 1996-01-24 1997-07-31 Hoechst Ag Mehrfach fucosylierte Dicarbonsäuren mit antiadhäsiven Eigenschaften
WO1997028174A1 (en) 1996-01-30 1997-08-07 Novartis Ag SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES
US6169077B1 (en) * 1996-01-30 2001-01-02 Glycotech Corp. Sialyl-Lewisa and sialyl-Lewisx epitope analogues
CA2247115C (en) 1996-03-01 2008-11-18 The Regents Of The University Of California Inhibition of selectin binding
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US5654412A (en) 1996-05-29 1997-08-05 Glycomed Incorporated Processes for the synthesis of sialyl Lewisx compounds
US5994402A (en) 1996-06-05 1999-11-30 Rotstein; Ori D. Anti-inflammatory and anti-pyretic method
US5919768A (en) * 1996-06-26 1999-07-06 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
EP0920437A1 (en) 1996-08-08 1999-06-09 Novartis AG Modified oligosaccharides
US5830871A (en) 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
GB9618520D0 (en) 1996-09-05 1996-10-16 Chiroscience Ltd Compounds and their therapeutic use
CA2266640C (en) 1996-09-27 2011-05-24 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6110897A (en) 1996-10-10 2000-08-29 Glycorex Ab Antiinflammatory cell adhesion inhibitors
AU733692B2 (en) * 1997-02-28 2001-05-24 Regents Of The University Of California, The Inhibition of cell-cell binding by lipid assemblies
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
SE9701127D0 (sv) * 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6193973B1 (en) * 1997-08-22 2001-02-27 B. David Tuttle Dietary supplement for boosting energy and increasing muscular strength
US5948628A (en) * 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
US6194657B1 (en) * 1998-10-24 2001-02-27 Arlington Industries, Inc. Mounting device
US6239368B1 (en) * 1998-01-03 2001-05-29 Arlington Industries, Inc. Siding box
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO1999043356A1 (en) 1998-02-25 1999-09-02 Hsc Research Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6037333A (en) * 1998-05-07 2000-03-14 Trustees Of Tufts College Microbe-inhibiting compositions
US6061983A (en) * 1998-06-01 2000-05-16 Mccleskey; Michael Removable utility connection floor box and method
AU773542B2 (en) * 1998-06-16 2004-05-27 Board Of Regents Of The University Of Oklahoma, The Glycosulfopeptides and methods of synthesis and use thereof
US6111197A (en) * 1998-09-04 2000-08-29 Layne; Harry R. Embeddable mounting device
CA2344652C (en) * 1998-09-21 2007-11-20 Otsuka Pharmaceutical Co., Ltd. Carboxymethylgalactose derivatives
DE69941031D1 (de) 1998-11-12 2009-08-06 Novolytics Inc Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
US6167671B1 (en) * 1998-12-21 2001-01-02 Steven D. Wilson Prefabricated concrete wall form system
US6172298B1 (en) * 1999-04-08 2001-01-09 Steven D. Norvelle Telescoping electrical distribution panel
EP1289552B1 (en) 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
WO2002022820A1 (en) 2000-09-12 2002-03-21 Genetics Institute, Llc Inhibition of stenosis or restenosis by p-selectin antagonists
EP1337539A2 (en) 2000-11-29 2003-08-27 Bracco International B.V. Linkable sialyl lewis x analogs
US20020132220A1 (en) 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US7087212B2 (en) * 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
EP1542704A1 (en) 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
EP1534725A2 (en) 2002-05-16 2005-06-01 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US6858802B2 (en) * 2002-06-14 2005-02-22 Randl Industries, Inc. Extension ring for electrical junction box installations
AU2003245595A1 (en) 2002-07-03 2004-01-23 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
CA2511174A1 (en) * 2002-12-20 2004-07-15 Glycomimetics, Inc. Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US6737576B1 (en) * 2003-05-16 2004-05-18 Thomas & Betts International, Inc. Electrical box assembly
WO2005054264A2 (en) 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
WO2005051920A2 (en) * 2003-11-19 2005-06-09 Glycomimetics, Inc. Specific antagonist for both e- and p-selectins
WO2005116088A2 (en) 2004-05-25 2005-12-08 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006105019A1 (en) 2005-03-25 2006-10-05 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
US20060287253A1 (en) 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
ES2397850T3 (es) 2005-09-02 2013-03-11 Glycomimetics, Inc. Inhibidores de pan-selectina heterobifuncionales

Also Published As

Publication number Publication date
USRE44778E1 (en) 2014-02-25
US20120004190A1 (en) 2012-01-05
PL2264043T3 (pl) 2018-04-30
HUE038246T2 (hu) 2018-10-29
AU2006284578B2 (en) 2011-01-27
JP2009507031A (ja) 2009-02-19
JP2012184268A (ja) 2012-09-27
EP1934236A1 (en) 2008-06-25
AU2006284578A1 (en) 2007-03-08
US20140178303A1 (en) 2014-06-26
DK1934236T3 (da) 2013-02-25
US8633303B2 (en) 2014-01-21
CN103626813A (zh) 2014-03-12
CN103626813B (zh) 2017-05-03
US20160361332A1 (en) 2016-12-15
EP1934236B1 (en) 2012-11-21
ES2397850T3 (es) 2013-03-11
US20070054870A1 (en) 2007-03-08
ES2651929T3 (es) 2018-01-30
PT1934236E (pt) 2012-12-26
US7989601B2 (en) 2011-08-02
CY1119721T1 (el) 2018-06-27
US20100204170A1 (en) 2010-08-12
PT2264043T (pt) 2018-01-19
SI2264043T1 (sl) 2018-01-31
CN101287741A (zh) 2008-10-15
CN101287741B (zh) 2014-05-07
WO2007028050A1 (en) 2007-03-08
PL1934236T3 (pl) 2013-04-30
US7728117B2 (en) 2010-06-01
DK2264043T3 (da) 2018-01-29
JP5209476B2 (ja) 2013-06-12
EP2264043B1 (en) 2017-11-08
HK1122041A1 (en) 2009-05-08
EP2264043A1 (en) 2010-12-22
LT2264043T (lt) 2017-12-11
CA2670130A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
HUE038246T2 (hu) Heterobifunkcionális pan-szelektin inhibitorok
IL179398A0 (en) Dpp-ib inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
ZA200802867B (en) Fap inhibitors
HK1124761A1 (en) Gsk-3 inhibitors gsk-3
IL178125A0 (en) Gsk-3 inhibitors
IL190078A0 (en) Kinase inhibitors
PL1943243T3 (pl) Inhibitory kinazy
IL172896A0 (en) Cxcr4 inhibition
GB0515327D0 (en) Comt inhibitors
GB0421355D0 (en) Inhibitors
GB0421356D0 (en) Inhibitors
GB0516967D0 (en) Inhibitors
GB2426539B (en) Sleeper
GB0524433D0 (en) Contents-relating arrangements
GB0503644D0 (en) Catstep I
GB0506443D0 (en) Novel inhibitors
GB2431102B (en) Vessel-filling arrangements
ZA200803287B (en) Kinase inhibitors
IL189985A0 (en) Kinase inhibitors
GB0513100D0 (en) Pansaver III
GB0408300D0 (en) Novel inhibitors
GB0509282D0 (en) Easy klik
GB0505150D0 (en) Ties
AU2005157V (en) PVHL1 Hakea laurina